PH24377A - Formulations suitable for the stabilisation of alpha-interferon - Google Patents
Formulations suitable for the stabilisation of alpha-interferonInfo
- Publication number
- PH24377A PH24377A PH34815A PH34815A PH24377A PH 24377 A PH24377 A PH 24377A PH 34815 A PH34815 A PH 34815A PH 34815 A PH34815 A PH 34815A PH 24377 A PH24377 A PH 24377A
- Authority
- PH
- Philippines
- Prior art keywords
- active ingredient
- alpha
- stabilisation
- interferon
- formulations suitable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The pharmaceutical forms are intended for topical administration and employ as vehicle for and stabiliser of the active ingredient a composition which specifically confers special stability on the active ingredient IFN alpha. The forms are essentially composed of hydroxyethylcellulose and gelatin and preferably contain highly purified IFN alpha which has been prepared by DNA recombination as active ingredient.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19863603444 DE3603444A1 (en) | 1986-02-05 | 1986-02-05 | PHARMACEUTICAL PREPARATIONS FOR STABILIZING INTERFERON ALPHA |
Publications (1)
Publication Number | Publication Date |
---|---|
PH24377A true PH24377A (en) | 1990-06-13 |
Family
ID=6293372
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PH34815A PH24377A (en) | 1986-02-05 | 1987-02-05 | Formulations suitable for the stabilisation of alpha-interferon |
Country Status (20)
Country | Link |
---|---|
EP (1) | EP0231816B1 (en) |
JP (1) | JPS62209024A (en) |
KR (1) | KR870007698A (en) |
AT (1) | ATE63823T1 (en) |
AU (1) | AU601712B2 (en) |
CA (1) | CA1295242C (en) |
DD (1) | DD284602A5 (en) |
DE (2) | DE3603444A1 (en) |
DK (1) | DK164202C (en) |
ES (1) | ES2028796T3 (en) |
FI (1) | FI86144C (en) |
GR (1) | GR3002270T3 (en) |
HU (1) | HU196560B (en) |
IE (1) | IE59697B1 (en) |
IL (1) | IL81472A0 (en) |
NO (1) | NO169638C (en) |
NZ (1) | NZ219169A (en) |
PH (1) | PH24377A (en) |
PT (1) | PT84243B (en) |
ZA (1) | ZA87793B (en) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5275804A (en) * | 1986-02-25 | 1994-01-04 | E. B. Michaels Research Associates, Inc. | Process and composition for oral hygiene |
DE3731255A1 (en) * | 1987-09-17 | 1989-04-06 | Boehringer Ingelheim Int | Stabilization of therapeutically active proteins in pharmaceutical preparations |
US5266310A (en) * | 1987-09-17 | 1993-11-30 | Boehringer Ingelheim International Gmbh | Stabilization of therapeutically active proteins in pharmaceutical preparations |
DE3803312A1 (en) * | 1988-02-04 | 1989-08-10 | Gerd Prof Dr Med Gross | Use of an interferon-containing gel |
NO179479C (en) * | 1988-03-11 | 1996-10-16 | Teikoku Seiyaku Kk | Process for the preparation of an intravaginal pharmaceutical preparation |
EP0374257B1 (en) * | 1988-05-06 | 1994-08-31 | Toray Industries, Inc. | STABLE INTERFERON $g(b) COMPOSITION |
US5389676A (en) * | 1991-03-22 | 1995-02-14 | E. B. Michaels Research Associates, Inc. | Viscous surfactant emulsion compositions |
US5244652A (en) * | 1991-03-22 | 1993-09-14 | E. B. Michaels Research Associates, Inc. | Viscous surface active composition |
WO1993006856A1 (en) * | 1991-10-11 | 1993-04-15 | Mark Cedric Gillies | Treating ophthalmic fibrosis using interferon-alpha |
US5863530A (en) * | 1991-10-11 | 1999-01-26 | Spruson & Ferguson | Treating ophthalmic fibrosis using interferon-α |
US6630168B1 (en) | 1997-02-20 | 2003-10-07 | Biomedicines, Inc. | Gel delivery vehicles for anticellular proliferative agents |
FI106465B (en) * | 1998-06-10 | 2001-02-15 | Suomen Punainen Risti Veripalv | A process for preparing virus-safe pharmaceutical compositions |
US6923966B2 (en) | 1999-04-08 | 2005-08-02 | Schering Corporation | Melanoma therapy |
JP4536194B2 (en) * | 2000-02-17 | 2010-09-01 | 大日本住友製薬株式会社 | Stable injectable formulation |
AU2001243431B2 (en) * | 2000-03-07 | 2006-05-25 | Rush University Medical Center | Compositions and methods for trapping and inactivating pathogenic microbes and spermatozoa |
US6328987B1 (en) * | 2000-11-03 | 2001-12-11 | Jan Marini Skin Research, Inc. | Cosmetic skin care compositions containing alpha interferon |
KR20050042032A (en) * | 2001-11-02 | 2005-05-04 | 세키스이가가쿠 고교가부시키가이샤 | Cytokine-inducing material and cytokine-inducing instrument |
US8137677B2 (en) * | 2005-10-06 | 2012-03-20 | Allergan, Inc. | Non-protein stabilized clostridial toxin pharmaceutical compositions |
CA2761963C (en) * | 2009-05-29 | 2018-03-20 | Filligent Limited | Composition for use in decreasing the transmission of human pathogens |
JP6185937B2 (en) * | 2012-03-01 | 2017-08-23 | ファーストストリング・リサーチ・インコーポレイテッドFirststring Research,Inc. | Alpha-connexin C-terminal (ACT) peptide-containing topical gel |
JP6081156B2 (en) * | 2012-11-15 | 2017-02-15 | アルケア株式会社 | Hydrogel |
DE102012222365A1 (en) | 2012-12-05 | 2014-06-05 | Aesculap Ag | Composition for use in the prophylaxis of post-surgical adhesions |
CN105530950A (en) * | 2013-06-09 | 2016-04-27 | 艾弗兰纳特有限公司 | Compositions comprising gc- macrophage activating factor and uses thereof |
WO2018143911A1 (en) | 2017-01-31 | 2018-08-09 | Kimberly-Clark Worldwide, Inc. | Antibacterial composition including benzoic acid ester and methods of inhibiting bacterial growth utilizing the same |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU1234383A (en) * | 1982-03-17 | 1983-09-22 | Inter-Yeda Ltd. | Interferon stabilised with polyvinyl-pyrrolidone |
JPS6061535A (en) * | 1983-08-24 | 1985-04-09 | エフ・ホフマン・ラ・ロシユ・ウント・コンパニ−・アクチエンゲゼルシヤフト | Pharmaceutical composition |
JPS6069037A (en) * | 1983-09-26 | 1985-04-19 | Sunstar Inc | External preparation for erythematosus |
EP0139286B1 (en) * | 1983-10-14 | 1991-08-21 | Sumitomo Pharmaceuticals Company, Limited | Prolonged sustained-release preparations |
US4680175A (en) * | 1984-02-07 | 1987-07-14 | Interferon Sciences, Inc. | Interferon administration vehicles |
CA1248450A (en) * | 1984-04-05 | 1989-01-10 | Kazuo Kigasawa | Soft patch |
JPS60228422A (en) * | 1984-04-26 | 1985-11-13 | Suntory Ltd | Stabilized preparation of physiologically active substance |
JPS60260523A (en) * | 1984-06-07 | 1985-12-23 | Asahi Chem Ind Co Ltd | Lyophilized drug composition of interferon |
-
1986
- 1986-02-05 DE DE19863603444 patent/DE3603444A1/en not_active Withdrawn
-
1987
- 1987-01-21 DE DE8787100792T patent/DE3770280D1/en not_active Expired - Fee Related
- 1987-01-21 ES ES198787100792T patent/ES2028796T3/en not_active Expired - Lifetime
- 1987-01-21 AT AT87100792T patent/ATE63823T1/en not_active IP Right Cessation
- 1987-01-21 EP EP87100792A patent/EP0231816B1/en not_active Expired - Lifetime
- 1987-02-03 CA CA000528832A patent/CA1295242C/en not_active Expired - Lifetime
- 1987-02-03 FI FI870457A patent/FI86144C/en not_active IP Right Cessation
- 1987-02-03 DD DD87299676A patent/DD284602A5/en not_active IP Right Cessation
- 1987-02-04 IE IE29587A patent/IE59697B1/en not_active IP Right Cessation
- 1987-02-04 HU HU87385A patent/HU196560B/en not_active IP Right Cessation
- 1987-02-04 AU AU68292/87A patent/AU601712B2/en not_active Ceased
- 1987-02-04 JP JP62024423A patent/JPS62209024A/en active Pending
- 1987-02-04 IL IL81472A patent/IL81472A0/en not_active IP Right Cessation
- 1987-02-04 NO NO870441A patent/NO169638C/en unknown
- 1987-02-04 DK DK058387A patent/DK164202C/en not_active IP Right Cessation
- 1987-02-04 PT PT84243A patent/PT84243B/en not_active IP Right Cessation
- 1987-02-04 ZA ZA87793A patent/ZA87793B/en unknown
- 1987-02-04 NZ NZ219169A patent/NZ219169A/en unknown
- 1987-02-05 KR KR870000912A patent/KR870007698A/en not_active Application Discontinuation
- 1987-02-05 PH PH34815A patent/PH24377A/en unknown
-
1991
- 1991-07-08 GR GR91400966T patent/GR3002270T3/en unknown
Also Published As
Publication number | Publication date |
---|---|
FI86144C (en) | 1992-07-27 |
HUT43494A (en) | 1987-11-30 |
NO870441D0 (en) | 1987-02-04 |
AU601712B2 (en) | 1990-09-20 |
NZ219169A (en) | 1990-04-26 |
DK164202B (en) | 1992-05-25 |
DK164202C (en) | 1992-10-19 |
PT84243B (en) | 1989-09-14 |
ZA87793B (en) | 1988-10-26 |
DK58387A (en) | 1987-08-06 |
EP0231816A3 (en) | 1987-09-23 |
ES2028796T3 (en) | 1992-07-16 |
NO169638C (en) | 1992-07-22 |
AU6829287A (en) | 1987-08-06 |
KR870007698A (en) | 1987-09-21 |
DE3603444A1 (en) | 1987-08-06 |
EP0231816A2 (en) | 1987-08-12 |
EP0231816B1 (en) | 1991-05-29 |
HU196560B (en) | 1988-12-28 |
DD284602A5 (en) | 1990-11-21 |
NO870441L (en) | 1987-08-06 |
NO169638B (en) | 1992-04-13 |
FI86144B (en) | 1992-04-15 |
GR3002270T3 (en) | 1992-12-30 |
ATE63823T1 (en) | 1991-06-15 |
PT84243A (en) | 1987-03-01 |
IE870295L (en) | 1987-08-05 |
IL81472A0 (en) | 1987-09-16 |
DE3770280D1 (en) | 1991-07-04 |
FI870457A (en) | 1987-08-06 |
JPS62209024A (en) | 1987-09-14 |
FI870457A0 (en) | 1987-02-03 |
IE59697B1 (en) | 1994-03-23 |
CA1295242C (en) | 1992-02-04 |
DK58387D0 (en) | 1987-02-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA87793B (en) | Formulations suitable for the stabilisation of alpha-interferon | |
HK1015137A1 (en) | Antiviral 4-substituted-2-deoxy-2,3-didehydro derivatives of alpha d-neuraminic acid | |
IL85523A (en) | Stable alpha interferon complex,its preparation and pharmaceutical compositions comprising it | |
CA2058428A1 (en) | Analgesic formulations | |
ES2009216A6 (en) | IL-1alpha derivatives and drugs. | |
AU7076887A (en) | Nasal administration of drugs | |
PT779805E (en) | SUSTAINED LIBERTACATION OF PEPTIDES OF PHARMACEUTICAL COMPOSITIONS | |
DK0395329T3 (en) | Composition in the form of a foam containing 5-aminosalicylic acid for intrarectal administration | |
IL108071A0 (en) | Substituted 4-phenyl-pyridones and 4-phenyl-2-alkoxypyridines their preparation and pharmaceutical compositions containing them | |
IL68456A0 (en) | Pharmaceutical compositions comprising perfluorohydrocarbons as vehicles | |
IL79816A0 (en) | Pharmaceutical composition comprising a drug-polymer matrix | |
AU1518492A (en) | Pharmaceutical compositions for transcutaneous administration | |
DK305087A (en) | BUPRENORPHIC CONTAINED PHARMACEUTICAL SUPPLY | |
GB2021409A (en) | Pharmaceutical composition | |
AU581855B2 (en) | 1-(4'-alkylsulphonylphenyl)-2-amino-1, 3-propanediol n-substituted derivatives | |
IE56229B1 (en) | 2-piperazinyl-or-homopiperazinyl-quinazoline derivatives their production and pharmaceutical compositions containing them | |
AU581856B2 (en) | 1-(4'-alkylthiophenyl)-2-amino-1, 3-propanediol N-substituted derivatives | |
IL106289A (en) | Phospholipid derivatives their preparation and pharmaceutical compositions containing them | |
GB1351437A (en) | N-substituted amino acids having antiviral anti-inflammatory or anti-tumour activity | |
EP0355899A3 (en) | Nucleotide derivatives | |
ES2091571T3 (en) | NEW ACTIVE PEPTIDIC DERIVATIVES IN THE CELL ADHESION PROCESSES, THEIR PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM. | |
ATE102934T1 (en) | FLUORINATED FLAVONACETIC ACID. | |
ES2135424T3 (en) | ORAL COMPOSITION BASED ON IBUPROFEN. | |
IT8723007A0 (en) | PHARMACEUTICAL COMPOSITIONS FOR ORAL USE WITH BILE ACIDS SEQUESTRATION ACTIVITY CONTAINING CHOLESTYRAMINE AS THE ACTIVE INGREDIENT, AND PROCEDURE FOR PREPARING THEM |